Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mesh & Prosthesis.
Ferzoco S, Clara ES, Tang SW, Hu J, Tan WB, Shabbir A, Lomanto D, Etherson K, Atkinson K, Khan S, Gwiti P, Viswanath Y, Munipalle PC, Berrevoet F, Dhondt L, Vanlander A, Matos-Azevedo AM, Fatás Cabeza JA, Zaragoza-Fernández C, Marín J, Navarro F, Rose B, Morfesis F, Armstrong N, Das Mohapatra S, O'Hara J, Camp C, Hughes D, Windsor AC, Blair L, Cox T, Huntington C, Oommen B, Kim M, Lincourt A, Augenstein V, Heniford T, Srivastava K, Martindale R, Scott J, Rosen M, Ray D, Bossi M, Tabbara M, Carandina S, Polliand C, Barrat C, Berta R, Wong C, Yang PC, Cheung PP, Chung TM, Chan CY, Lai CH, Tang CN, Li KW, Shen YM, Li Q, Chen J, Sun L, Chen FQ, Sharma M, Satija N, Mitura K, Garnysz K, Skolimowska-Rzewuska M, Wyrwas K, Kumar S, Lee S, Alves A, Pompee C, Chirat S, Drevon-Gaillot E, Clermont G, Tung K, Yang G. Ferzoco S, et al. Among authors: dhondt l. Hernia. 2015 Apr;19 Suppl 1:S147-56. doi: 10.1007/BF03355343. Hernia. 2015. PMID: 26518793 No abstract available.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.10.828. Online ahead of print. Ann Oncol. 2024. PMID: 39528049 Free article.
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).
Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, López-Campos F, Ost P, Roumeguere TA, Herrera-Imbroda B, D'Hondt LA, Quivrin M, Gontero P, Villà S, Khaled H, Fournier B, Musoro J, Krzystyniak J, Pretzenbacher Y, Loriot Y. Tombal BF, et al. Eur Urol Oncol. 2024 Oct;7(5):1051-1060. doi: 10.1016/j.euo.2024.01.009. Epub 2024 Jan 24. Eur Urol Oncol. 2024. PMID: 38272747 Free article. Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
105 results